

Journal of Endocrinological Investigation

Thyroid function in Klinefelter syndrome: a multicenter study from KING group

--Manuscript Draft--

Manuscript Number:	JENI-D-18-00755R1
Full Title:	Thyroid function in Klinefelter syndrome: a multicenter study from KING group
Article Type:	Original Article
Funding Information:	
Abstract:	<p>Purpose</p> <p>The prevalence and the etiopathogenesis of thyroid dysfunctions in Klinefelter syndrome (KS) are still unclear. The primary aim of this study was to evaluate the pathogenetic role of hypogonadism in the thyroid disorders described in KS, with the scope to distinguish between genetic alterations or hormonal involvement. Therefore, we evaluated thyroid function in KS and in non-KS hypogonadal patients.</p> <p>Methods</p> <p>This is a case-control multicentre study from KING group: Endocrinology clinics in university-affiliated medical centres. One hundred seventy four KS, and sixty-two non-KS hypogonadal men were enrolled. The primary outcome was the prevalence of thyroid diseases in KS and in non-KS. Changes in hormonal parameters were evaluated. Exclusion criterion was secondary hypothyroidism. Analyses were performed using Student's t test. Mann-Whitney test and chi-square test.</p> <p>Results</p> <p>FT4 was significantly lower in KS vs non-KS. KS and non-KS presented similar TSH and testosterone levels. Hashimoto's thyroiditis (HT) was diagnosed in 7% of KS. Five KS developed hypothyroidism. The ratio FT3/FT4 was similar in both groups. TSH index was 1.9 in KS and 2.3 in non-KS. Adjustment for differences in age, sample size and concomitant disease in multivariate models did not alter the results.</p> <p>Conclusions</p> <p>We demonstrated in KS no etiopathogenic link to hypogonadism or change in the set point of thyrotrophic control in the altered FT4 production. These results suggest possible deiodinase impairment. The prevalence of HT in KS was similar to normal male population, showing absence of increased risk of HT associated with the XXY karyotype.</p>
Corresponding Author:	Daniela Pasquali, M.D., Ph.D University of Campania "L. Vanvitelli" ITALY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Campania "L. Vanvitelli"
Corresponding Author's Secondary Institution:	
First Author:	Giancarlo Balercia
First Author Secondary Information:	
Order of Authors:	Giancarlo Balercia Marco Bonomi Vito Angelo Giagulli Fabio Lanfranco

	Vincenzo Rochira
	Antonio Giambersio
	Giacomo Accardo
	Daniela Esposito
	Stefano Allasia
	Biagio Cangiano
	Sara De Vincentis
	Rosita A Condorelli
	Aldo Calogero
	Daniela Pasquali, M.D., Ph.D
Order of Authors Secondary Information:	
Author Comments:	<p>We complete and sign the Authorship Change Form,</p> <p>Sincerely yours Daniela Pasquali</p>
Response to Reviewers:	<p>Comments and answers</p> <p>Reviewer #1: In this paper titled "Thyroid function in Klinefelter syndrome (KS): a multicenter study from KING group", the authors compared thyroid function in a group of patients with Klinefelter with a group of hypogonadal patients. The aim of the study is to clarify the prevalence and etiology of hypothyroidism in KS patients. Thyroid function was studied using serum hormonal and antibody concentration. The authors conclude that there is no etiopathogenic link between KS and hypothyroidism, and that the KS patients present an impaired production of T4 by the thyroid gland, with an adaptive type II deiodinase activity that allows a normal peripheral circulating amount of FT3 and normal TSH levels.</p> <p>In the abstract, page 2 line 19 (it is in line 9): the number of KS patients (174) does not coincide with the number in table 1 (176). The correct number of KS patients is 174. This has been corrected here and throughout the manuscript.</p> <p>Page 4, lane 2: Authors should check that the number of KS patients declared (174) is correct. The correct number of KS patients is 174. This has been corrected here and throughout the manuscript.</p> <p>The same check should be made at every point where this number is being reported [page 4 line 19 (this in in line 9) and table 1]. The correct number of KS patients is 174. This has been corrected here and throughout the manuscript.</p> <p>Page 7 line 17 The authors should consider the following review: Mol Cell Endocrinol. 2018 May 15;467:49-59. doi: 10.1016/j.mce.2017.11.006 as a introduction to the behavioral impact, if any, of the slight TH derangements here found (see also: Endocrine. 2015 Jun;49(2):333-8. doi: 10.1007/s12020-014-0520-7. and Mol Hum Reprod. 2010 Jun;16(6):418-24. doi: 10.1093/molehr/gaq022.) highlighting that the ejaculatory control has never been studied in KS.</p> <p>We considered these article and, as requested, included them in the discussion.</p> <p>Authors may consider to delete the figure 1 that is not significant and to replace it with a figure of FT4 levels, which are significantly different between the two groups analyzed.</p> <p>We modified the figures (Figure 1, 2 and 3), as requested.</p> <p>Reviewer #2: The manuscript by Dr Balercia et al entitled "Thyroid function in Klinefelter syndrome: a multicenter study from KING group" investigates the thyroid function in a relevant number of KS patients. This research finds that the prevalence of thyroid autoimmune disorders in KS patients is not different from the general population and that KS patients show mildly reduced FT4 levels compared to another hypogonadic control group. This is a multicentric study, conducted by specialists who</p>

	<p>are experts of KS. These findings are somehow confirmatory of previous studies.</p> <p>Major criticisms</p> <ol style="list-style-type: none"> 1) It is unclear how the work is designed to distinguish between "genetic alterations or hormonal involvement". This sentence should be rephrased. The sentence was reworded to enhance its clarity. 2) Taking into account that FT4 measurement is so critical for the results of this work, the percentage of the different assays and manufacturer employed to measure FT4 should be indicated in the methods section. We reported the coefficient of variation for FT4 assay in Methods (Daniela per favore vedi il testo). 3) If "an altered T4 production by the thyroid gland" is present and TSH levels are not increased (compared to controls) this suggests a different set point of the thyroid axis in the two experimental groups. This hypothesis is more plausible than alterations based only on increased D2 activity. We agree with the Reviewer. Therefore, and we removed all the discussion on deiodinase from the Abstract and the Discussion, considering it as a possible starting point for further studies. 4) To interpret adequately thyroid function data, iodine intake and urinary iodine should have been measured. This is an important limitation of the study. We included these comments among possible future research development in KS patients. 5) From the results section it is unclear if the prevalence of TH, in the two experimental groups, is different or not. Since this is not the case, the data can be reported in table 1. We reported the prevalence of TH in Table 1. 6) The involvement of D2 activation in this context is not enough supported by the results or by previous findings. For this reason, this speculation, should be removed from the abstract and discussion. We agree with the Reviewer. Therefore, and we removed all the discussion on deiodinase from the Abstract and the Discussion, considering it as a possible starting point for further studies. See also Q3.
<p>Suggested Reviewers:</p>	<p>Anders Juul anders.juul@regionh.dk International expert of Klinefelter syndrome</p> <hr/> <p>Stefan Schlatt stefan.schlatt@ukmuenster.de An international expert of Klinefelter syndrome</p>

[Click here to view linked References](#)

1 **Thyroid function in Klinefelter syndrome: a multicenter study from** 2 **KING group**

3 Giancarlo Balercia,¹ Marco Bonomi,^{2,3} Vito A. Giagulli,⁴ Fabio Lanfranco,⁵ Vincenzo
4 Rochira,^{6,7} Antonio Giambersio,⁸ Giacomo Accardo,⁹ Daniela Esposito,¹⁰ Stefano
5 Allasia,⁵ Biagio Cangiano,^{2,3} Sara De Vincentis,^{6,7} Rosita A. Condorelli,¹¹ Aldo
6 Calogero,¹¹ and Daniela Pasquali,⁹ on behalf of KING group.

7 ¹Division of Endocrinology, Department of Clinical and Molecular Sciences, Umberto I Hospital,
8 Polytechnic University of Marche, Ancona, Italy; ²Department of Clinical Sciences and Community Health,
9 University of Milan, Milan, Italy; ³Division of Endocrine and Metabolic Diseases, and Lab of Endocrine and
10 Metabolic Research - IRCCS Istituto Auxologico Italiano, Milano, Italy; ⁴Outpatient Clinic for
11 Endocrinology and Metabolic Diseases, Conversano Hospital, Conversano, Bari, Italy; ⁵Division of
12 Endocrinology, Diabetology, and Metabolism, Department of Medical Sciences, University of Turin, Turin,
13 Italy; ⁶Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of
14 Modena and Reggio Emilia, Modena, Italy; ⁷Unit of Endocrinology, Department of Medical Specialties,
15 Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy; ⁸Health Center
16 "Maria Teresa di Calcutta" Potenza, Italy; ⁹Department of Advanced Medical And Surgical Sciences,
17 University of Campania "Luigi Vanvitelli", Naples, Italy, ¹⁰Department of Internal Medicine and Clinical
18 Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
19 ¹¹Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico",
20 Catania, Italy.

21
22
23 **Short title: Thyroid and Klinefelter syndrome.**

24 *Correspondence and reprint request:*

25 Daniela Pasquali, MD, PhD

26 Endocrinology Unit,

27 Department of Advanced Medical And Surgical Sciences, University of Campania "Luigi
28 Vanvitelli", Naples 80138, Italy.

29 E-mail: daniela.pasquali@unicampania.it

30 Phone: +393394731411

31 Author 1, 2, 3, 4 and 5 all contributed equally and should be considered co-first authors

32
33 **Disclosure summary:** The authors have nothing to disclose

34 **Acknowledgments** This study was performed on behalf of the Klinefelter ItaliaN Group (KING). Coordinators:
35 Antonio Aversa (Catanzaro), Giancarlo Balercia (Ancona), Marco Bonomi (Milan), Aldo Calogero (Catania), Giovanni
36 Corona (Bologna), Francesco Giorgino (Bari), Andrea Fabbri (Rome), Alberto Ferlin (Padua), Emanuele Ferrante
37 (Milan), Felice Francavilla (L'Aquila), Vito Giagulli (Conversano, Bari), Emmanuele Jannini (Rome), Fabio Lanfranco
38 (Turin), Mario Maggi (Florence), Daniela Pasquali (Naples), Rosario Pivonello (Naples), Alessandro Pizzocaro (Milan),
39 Antonio Radicioni (Rome), Vincenzo Rochira (Modena), Linda Vignozzi (Florence). Members: Marco Barchi (Rome),
40 Biagio Cangiano (Milan), Rosita A. Condorelli (Catania), Giuliana Cordeschi (L'Aquila), Settimio D'Andrea
41 (L'Aquila), Antonella Di Mambro (Padua), Carlo Foresta (Padua), Sandro Francavilla (L'Aquila), Andrea Garolla
42 (Padua), Lara Giovannini (Ancona), Antonio R.M. Granata (Modena), Sandro La Vignera (Catania), Giovanna Motta
43 (Turin), Luciano Negri (Milan), Fiore Pelliccione (Milan), Luca Persani (Milan), Ciro Salzano (Naples), Daniele Santi
44 (Modena), Riccardo Selice (Padua), Manuela Simoni (Modena), Carla Tatone (L'Aquila), Giacomo Tirabassi (Ancona),
45 Alberto Stefano Tresoldi (Milan) and Enzo Vicari (Catania). The KING belongs to the Italian Society of Andrology and
46 Sexual Medicine (SIAMS) and aims to promote all the activities, clinical, research, and informative, concerning KS in
47 Italy.

48 **Keywords:** Klinefelter syndrome, Testosterone, Hypergonadotropic hypogonadism, Thyroid
49 hormones, Thyroid diseases, Hashimoto's thyroiditis

Abstract

Purpose: The prevalence and the etiopathogenesis of thyroid dysfunctions in Klinefelter syndrome (KS) are still unclear. The primary aim of this study was to evaluate the pathogenetic role of hypogonadism in the thyroid disorders described in KS, with the scope to distinguish between patients with KS and hypogonadism due to other causes (Kallmann syndrome, idiopathic hypogonadotropic hypogonadism, iatrogenic hypogonadism and acquired hypogonadotropic hypogonadism after surgical removal of pituitary adenomas) called non-KS. Therefore, we evaluated thyroid function in KS and in non-KS hypogonadal patients.

Methods: This is a case-control multicentre study from KING group: Endocrinology clinics in university-affiliated medical centres. One hundred seventy four KS, and sixty-two non-KS hypogonadal men were enrolled. The primary outcome was the prevalence of thyroid diseases in KS and in non-KS. Changes in hormonal parameters were evaluated. Exclusion criterion was secondary hypothyroidism. Analyses were performed using Student's t test. Mann-Whitney test and chi-square test.

Results: FT4 was significantly lower in KS vs non-KS. KS and non-KS presented similar TSH and testosterone levels. Hashimoto's thyroiditis (HT) was diagnosed in 7% of KS. Five KS developed hypothyroidism. The ratio FT3/FT4 was similar in both groups. TSH index was 1.9 in KS and 2.3 in non-KS. Adjustment for differences in age, sample size and concomitant disease in multivariate models did not alter the results.

Conclusions: We demonstrated in KS no etiopathogenic link to hypogonadism or change in the set point of thyrotrophic control in the altered FT4 production. The prevalence of HT in KS was similar to normal male population, showing absence of increased risk of HT associated with the XXY karyotype.

Introduction

Klinefelter Syndrome (KS) is the most frequent observed sex chromosomal anomaly, with an estimated frequency of 1:500 to 1:1000 men (1). The classic form of KS, which is present in the 80–90 % of the cases, is defined by a 47,XXY karyotype, low serum testosterone (T) coupled with elevated gonadotropins, small and firm testes, azoospermia, and tall stature. The clinical presentation of KS syndrome is widely heterogeneous. Only about one in 10 males with KS is diagnosed before puberty and 25-50% in adult age, often during infertility investigation. KS is associated with several clinical conditions coming from both the genetic abnormalities, and hypogonadism. KS patients present several comorbidities including cardiovascular diseases, osteoporosis, diabetes mellitus, and metabolic syndrome, leg ulcers, mostly related to hypogonadism (2-5). Consequently, KS males need lifelong testosterone replacement treatment. Yet, the therapy does not counteract or prevent all comorbidities. It is still unclear whether the extra chromosome X adds an extra testosterone-independent feature to the complexity of KS comorbidities. Thus, the relationship between clinical phenotype, endocrine dysfunction, KS comorbidities and genetic background needs further investigations (1). Various thyroid abnormalities were described, mostly in old studies based on few participants, the most common being a low response in serum TSH to a TRH stimulation test (6,7). KS had a general shift toward lower values in distribution of serum FT4 with no compensatory increase in serum TSH (8). The most likely mechanism suggested is a decrease or change in set point of thyrotrophic control of thyroid function (8). Recently a study demonstrated that pubertal KS patients have significantly lower FT3 serum levels than healthy age-matched boys, whereas TSH and FT4 are in the normal reference range (9). Furthermore, some authors have recently analysed KS comorbidities using data from the Danish National Patient Registry (10). They searched for differentially expressed genes in peripheral blood and found several expression signatures that correlated with KS status either

1 positively or negatively. Genes involved in ‘abnormal thyroid hormone metabolism’ were
2 upregulated (10).
3

4 To better clarify the prevalence of thyroid diseases and the role of 47XXY as well as the
5 hypogonadism in thyroid dysregulation, we studied thyroid function in one hundred seventy four
6
7 patients with KS compared with non-KS hypogonadal men.
8
9

14 **Subjects and Methods**

17 **Patient population**

18
19 We performed a multicentre case control-study, involving the national network of academic or
20
21 general hospitals named KING (Klinefelter ItaliaN Group). The entire cohort consisted of one
22
23 hundred seventy four consecutive KS subjects, and sixty-two age-matched non-KS hypogonadal
24
25 men recruited among those regularly attending KING centres since 2015. Inclusion criteria were: i)
26
27 a verified KS karyotype (47, XXY); ii) a written informed consent. Patients underwent a complete
28
29 medical and family history evaluation. We examined thyroid function, and thyroid antibodies (Ab).
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

41 **Collection of samples**

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

58 **Biochemical data**

1 As we recruited patients regularly attending KING centres, different methods have been used. In the
2 majority of the cases, serum TSH, FT4, FT3 concentrations were measured by chemiluminescent
3 immunometric assay (Roche Diagnostics GmbH, Mannheim, Germany). The coefficient of
4 variation was 5.4% for the FT4 assay. The manufacturer's reference limits are TSH (0.35–
5 5.5 mIU/L), FT4 (10.2–31 pmol/L), and FT3 (3.5–6.5 pmol/L). Detection limit for TSH is 0.005
6 μ IU/mL, functional sensitivity 0.014 μ IU/mL. Thyroid function alteration was classified according
7 to the American Thyroid Association guidelines (11, 12). Clinically overt hyperthyroidism,
8 undetectable to less than 0.1mIU/L TSH, more than normal range FT3, and FT4; subclinical
9 hyperthyroidism, undetectable to less than 0.1 mIU/L TSH and FT3 and FT4 in the normal range
10 without exogenous T4 intake; clinically overt hypothyroidism, TSH above the upper limit of the
11 normal range (5mIU/L in our assay) and FT4 below 10.2 pmol/L; and subclinical hypothyroidism,
12 TSH above the upper limit of the normal range and FT4 in the normal range (11,12). Total
13 testosterone was measured by immunoassay using a commercial Kit, automated immunoassays
14 (DiaSorin Liaison, Saluggia, VC, Italy).

15 **Exclusion criteria**

16 KS patients with mosaic forms of chromosomal aneuploidy or any other structural or numerical
17 karyotype anomaly, with AZF microdeletions, were excluded. Moreover, exclusion criterion in non-
18 KS control group was also secondary hypothyroidism defined as undetectable to less than 0.1
19 mIU/L TSH, FT4, and FT3 in the lower range without exogenous T4 intake. Subjects with
20 clinically overt thyroid dysfunction, or personal or family history of thyroid disease were excluded
21 from the control sample, which was, therefore, a population of clinically normothyroidal
22 individuals.

23 **Statistical analysis**

24 Data were tabulated on a spreadsheet and analysed with SPSS statistics 17 software. We calculated
25 mean and standard deviation for continuous variables.

1 Analyses were performed using Student's t test. TSH and testosterone were analysed using Mann-
2 Whitney test and, for TPO antibodies chi-square test analysis was performed.

3 All analysis was two-sided and p values minor 0.05 were considered statistically significant.

4
5 This study was approved by "Comitato Etico Seconda Università degli studi di Napoli- Azienda
6
7
8
9
10
11
12 Ospedaliera Universitaria SUN-AORN Ospedale dei Colli" n 1489, 26.10.2015 to DP.

13 14 15 16 17 **Results**

18 19 **Demographic characteristics of the study groups**

20
21
22 The mean age at study entry was 40.6 ± 1 (mean \pm SD; range, 16–59) and 40.0 ± 2.4 (mean \pm SD;
23
24 range, 16–71) years in KS and in non-KS respectively. The non-KS group was composed by thirty-
25
26 three Kallmann syndrome patients, seventeen patients with idiopathic hypogonadotropic
27
28 hypogonadism, four patients were affected by iatrogenic hypogonadism, and eight by acquired
29
30 hypogonadotropic hypogonadism after surgical removal of pituitary adenomas (table 2). The
31
32 comparison between KS and non-KS group allowed evaluating the impact of the hypogonadal
33
34 condition and the genetic origin of thyroid function alterations in KS. All the subjects were under
35
36 testosterone replacement treatment. T levels were similar in both KS (324 ± 69 ng/dl) and non-KS
37
38 (284.7 ± 36 ng/dl), and in both groups at the lower end of the normal range.

39 40 41 **Hashimoto's thyroiditis in KS vs. non-KS patients**

42
43
44 In KS group 7% of the patients showed TPOAb positivity, while 4% out of sixty-two hypogonadal
45
46 non-KS group had HT (Table 1). Five KS with HT were diagnosed with hypothyroidism and treated
47
48 with L-Thyroxine substitutive therapy.

49 50 51 **Hypothalamic–pituitary–thyroid axis dysregulation in KS**

52
53
54 Serum FT4 was significantly lower in men with KS versus non-KS [mean (SD): 10.69 (0.2) vs. 11.7
55
56 (0.4) pg/ml; $p < 0.006$] (Table 1). The FT3/FT4 ratio was similar in KS and in non-KS group (0.32
57
58 vs. 0.29, $p < 0.06$) (Figure 2). Nevertheless, KS and non-KS patients showed similar TSH and total T
59
60
61
62
63
64
65

1 levels [TSH: mean (SD): 1.61 (0.87) vs. 1.75 (1.2) p= 0.1; testosterone mean (SD): 324 (69) vs. 284
2 (36) ng/dl respectively p = 0.2] (Table 1). We calculated TSH Index, an accurate estimation of the
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Discussion

The etiopathogenesis of thyroid dysfunction in KS is still under debate. Here we show lower FT4 in KS, with no changes in FT3 and TSH levels. We have not found a higher prevalence of HT in KS.

The cross talk between thyroid and gonadal hormones is well known. Thyroid hormone regulation of sex steroid synthesis and action in both the brain and gonads are important for gonad development and brain sexual differentiation (15, 16). Thyroid transcription factor-1, a homeobox gene that regulates the transcriptional activity of thyroid-specific genes in thyroid follicular cells, occupies a central position within gene networks involved in the hypothalamic control of GnRH production (17). The effects of thyroid hormones in men and their correlations with sexual behaviour are not yet clear even though several studies show an association between thyroid diseases and altered sexual function (hypoactive sexual desire disorder, premature and delayed ejaculation, and erectile dysfunction) (18). KS patients have sexual dysfunctions not specifically associated with the syndrome but related to hypogonadism (19) although the ejaculatory control in this category of patients has not yet been studied.

To elucidate if the thyroid dysfunction in KS is related to the peculiarity of 47XXY condition and/or to T deficiency status, we analysed the occurrence of thyroid diseases in KS and in non-KS hypogonadal men. We have utilized data from a national multicentre study, to overcome the main problem arising from KS studies, the small sample size, that makes difficult to draw strong clinical conclusions. We confirm that males with KS have a shift toward lower values in distribution of serum FT4 (8). In particular, we have found a significant reduction of FT4 level in KS compared to

1 non-KS, with no statistical differences in TSH and FT3 levels. To verify the hypothesis of an
2 altered set point of thyrotrophic control of thyroid function in KS (8), we have performed TSH
3 index calculation. TSH index is an “FT4-adjusted TSH” that corrects for any physiological TSH
4 suppression, to provide a true estimate of pituitary thyrotrophic function and any pathological
5 pituitary suppression (14). TSH index was not statistically different in KS and non-KS, suggesting
6 an adequate hypothalamic-pituitary-thyroid axis control. We could speculate that, since in healthy
7 and iodine-sufficient individuals, the majority of thyroid hormone produced is T4, synthesized
8 exclusively by the thyroid gland, with a smaller amount (~20%) of T3, which is produced by the
9 thyroid and in peripheral tissues via deiodination of circulating T4, KS patients could have an
10 altered T4 production by the thyroid gland. The novel approach with the comparison of FT4 levels
11 between KS and non-KS patients give us the opportunity to clarify that T deficit, independently of
12 when it started, cannot be considered as a causal determinant in the pathophysiology of this
13 condition. Metabolic syndrome and insulin resistance are specific features of KS (1-3, 20-22) and
14 FT3/FT4 ratio has a better predictive power for metabolic syndrome than TSH (23). We found
15 comparable FT3/FT4 ratio both in KS and in non-KS, suggesting a similar predisposition to
16 increased risk of metabolic syndrome parameters and insulin resistance. Then we took the
17 opportunity to study the prevalence of Hashimoto’s thyroiditis (HT) among KS that resulted to be
18 7.0%. The prevalence of HT in KS was similar to that reported in healthy male volunteers in the
19 Pescopagano survey (24,25). In fact, in this comprehensive study of thyroid disease in Italy 17.3 %
20 of women and 7.0 % of male were affected by HT (24,25). The X chromosome contains the largest
21 number of immune-related genes of the whole human genome (26). Skewed X chromosome
22 inactivation has been considered one of the key factors that influence the female predisposition to
23 autoimmunity (27). Laboratory studies have shown high levels of autoantibodies to the thyroid
24 gland among people with KS (28). An English national cohort study of people with KS, found
25 significantly increased risks of several autoimmune diseases, including acquired hypothyroidism
26 (29). The extra X chromosome could predispose KS to higher prevalence of HT. Our Italian

1 national cohort results do not support this hypothesis and are in contrast with previous studies, in
2 particular considering the prevalence of HT in our KS cohort. This could be explained by the limits
3 of a dataset from hospital discharge records and/or the diagnostic criteria of HT (28,29).
4
5 Furthermore, a recent study based on data from the Danish National Patient Registry (10), analysed
6
7 KS comorbidities, searching for differentially expressed genes in peripheral blood. There were
8
9 genes causative of several Online Mendelian Inheritance in Man (OMIM) diseases such as
10
11 ‘abnormal thyroid hormone metabolism’, ‘epilepsy’ and ‘deafness’. These data indicate that more
12
13 factors are involved in thyroid dysregulation in KS other than increased risk of autoimmune
14
15 diseases. In previous studies, the most likely mechanism of thyroid abnormalities found in KS is an
16
17 alteration in set point of thyrotrophic regulation of thyroid function (6-9). It is quite difficult to
18
19 establish what are the causes and the effects of thyroid dysfunction in KS. However, we can exclude
20
21 the influence of hypogonadism leading to a dysregulation of hypothalamic–pituitary–thyroid axis.
22
23

24 In conclusion, our study indicates that KS present an impaired production of T4 by the thyroid
25
26 gland, suggesting a different set point of the thyroid axis versus patients with hypogonadism due to
27
28 other causes. No evidences of etiopathogenetic link to the hypogonadal status or change in set point
29
30 of thyrotrophic control were found. Further studies are needed to better understand the underlying
31
32 mechanism(s) of thyroid dysregulation that may include evaluation of deiodinase activity, iodine
33
34 intake and urinary iodine excretion.
35
36

37 **Funding**

38 This research did not receive any specific grant from any funding agency in the public, commercial
39
40 or not-for-profit sector.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Bonomi M, Rochira V, Pasquali D, Balercia G, Jannini EA, Ferlin A; Klinefelter ItaliaN Group (KING) (2017) Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism. *J Endocrinol Invest* 40:123-134
2. Kanakis GA, Nieschlag E (2018) Klinefelter syndrome: more than hypogonadism. *Metabolism* 286:135-144
3. Calogero AE, Giagulli VA, Mongioì LM, Triggiani V, Radicioni AF, Jannini EA, Pasquali D; Klinefelter ItaliaN Group (KING) (2017) Klinefelter syndrome: cardiovascular abnormalities and metabolic disorders. *J Endocrinol Invest* 40:705-712
4. Salzano A, Arcopinto M, Marra AM, et al (2016) Klinefelter syndrome, cardiovascular system, and thromboembolic disease: review of literature and clinical perspectives. *Eur J Endocrinol* 175:R27-40
5. Di Minno MN, Esposito D, Di Minno A, et al (2015) Increased platelet reactivity in Klinefelter men: something new to consider. *Andrology* 3:876-878
6. Smals AG, Kloppenborg PW, Lequin RL, Beex L, Ross A, Benraad TJ (1977) The pituitary-thyroid axis in Klinefelter's syndrome. *Acta Endocrinol (Copenh)* 84:72-79
7. Wortsman J, Moses HW, Dufau ML (1986) Increased incidence of thyroid disease among men with hypergonadotropic hypogonadism. *Am J Med* 80 1055-1059
8. Bjørn AM, Bojesen A, Gravholt CH, Laurberg PJ (2009) Hypothyroidism secondary to hypothalamic-pituitary dysfunction may be part of the phenotype in Klinefelter syndrome: a case-control study. *J Clin Endocrinol Metab* 94:2478-2481
9. Tahani N, Ruga G, Granato S, et al (2017) A combined form of hypothyroidism in pubertal patients with non-mosaic Klinefelter syndrome. *Endocrine* 55:513-518

- 1 10. Belling K, Russo F, Jensen AB, et al (2017) Klinefelter syndrome comorbidities linked to
2 increased X chromosome gene dosage and altered protein interactome activity. *Hum Mol*
3
4
5 3 Gen 26:1219–1229
6
- 7 4 11. Jonklaas J, Bianco AC, Bauer AJ, et al (2014) American Thyroid Association Task Force on
8
9
10 5 Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared
11
12 6 by the American Thyroid Association task force on thyroid hormone replacement. *Thyroid*
13
14 7 24: 1670-1751
15
- 16 12. Ross DS, Burch HB, Cooper DS, et al (2016) American Thyroid Association Guidelines for
17 8
18
19 9 diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid*
20
21
22 10 26:1343-1421
23
- 24 11 13. Aghini-Lombardi F, Antonangeli L, Martino E, et al (1999) The spectrum of thyroid
25
26
27 12 disorders in an iodine-deficient community: the Pescopagano survey. *J Clin Endocrinol*
28
29 13 *Metab* 84 561–566
30
- 31 14 14. Jostel A, Ryder WD, Shalet SM (2009) The use of thyroid function tests in the diagnosis of
32
33
34 15 hypopituitarism: definition and evaluation of the TSH Index. *Clin Endocrinol (Oxf)* 71:529-
35
36 16 534
37
- 38 15. Duarte-Guterman P, Navarro-Martín L, Trudeau VL (2014) Mechanisms of crosstalk
39
40
41 18 between endocrine systems: regulation of sex steroid hormone synthesis and action by
42
43
44 19 thyroid hormones. *Gen Comp Endocrinol* 203:69-85
45
- 46 16. A. Wayne Meikle (2004) The Interrelationships Between Thyroid Dysfunction and
47
48
49 21 Hypogonadism in Men and Boys. *Thyroid* 14 Suppl 1:S17-25
50
- 51 17. De Felice M, Di Lauro R (2004) Thyroid development and its disorders: genetics and
52
53
54 23 molecular mechanisms. *Endocr Rev* 25:722-746
55
- 56 18. Carosa E, Lenzi A, Jannini EA (2018) Thyroid hormone receptors and ligands, tissue
57
58
59 25 distribution and sexual behaviour. *Mol Cell Endocrinol* 467:49-59
60
- 61 19. Vignozzi L, Corona G, Forti G; Jannini EA, Maggi M (2010) Clinical and therapeutic
62
63
64
65

20. Pasquali D, Arcopinto M, Renzullo A, et al (2013) Cardiovascular abnormalities in Klinefelter syndrome. *Int J Cardiol* 168:754-759
21. Groth KA, Skakkebaek A, Høst C, Gravholt CH, Bojesen A.J (2013) Clinical review: Klinefelter syndrome--a clinical update. *J Clin Endocrinol Metab* 98:20-30
22. Salzano A, D'Assante R, Heaney LM, et al (2018) Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectives. *Endocrine* 61:194-203
23. Park SY, Park SE, Jung SW, Jin HS, Park IB, Ahn SV, Lee S (2017) Free triiodothyronine/free thyroxine ratio rather than thyrotropin is more associated with metabolic parameters in healthy euthyroid adult subjects. *Clin Endocrinol (Oxf)* 87:87-96
24. Aghini-Lombardi F, Antonangeli L, Martino E, et al (1999) *J Clin Endocrinol Metab* 84:561-566
25. McLeod DS, Cooper DS (2012) The incidence and prevalence of thyroid autoimmunity. *Endocrine* 42:252-265
26. Zaletel K, and Gaberšček S (2011) Hashimoto's Thyroiditis: From Genes to the Disease. *Curr Genomics* 12:576-588
27. Brix TH, Knudsen GP, Kristiansen M, Kyvik KO, Orstavik KH, Hegedüs L (2005) High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. *J Clin Endocrinol Metab* 90:5949-5953
28. Vallotton M, Forbes A (1967) Autoimmunity in gonadal dysgenesis and Klinefelter's syndrome. *Lancet* 289:648-651
29. Seminog OO, Seminog AB, Yeates D, Goldacre MJ (2015) Associations between Klinefelter's syndrome and autoimmune diseases: English national record linkage studies. *Autoimmunity* 48:125-128

1 **Legends to figures**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1. FT4 levels in Klinefelter syndrome vs. non-Klinefelter syndrome

Figure 2. FT3/FT4 ratio in Klinefelter syndrome vs. non-Klinefelter syndrome. Data are expressed as mean ± SD

Figure 3. TSH index in Klinefelter syndrome vs. non-Klinefelter syndrome. Data are expressed as Mean ± SD.




Figure 1




Figure 2




Figure 3


Table 1. Clinical, demographical and hormonal data of subjects with Klinefelter syndrome (KS) or with hypogonadism due to other causes (non-KS).

	KS	non-KS	p
Number of patients	174	62	
Hashimoto's thyroiditis (prevalence)	7%	4%	
Age (years)	40.6 ± 1.1	40.0 ± 2.4	ns
Testosterone (ng/dl)	324.3 ± 69	284.7 ± 36.5	0.05
TSH (IU/L)	1.83 ± 0.1	2.02 ± 0.1	ns
FT3 (pmol/L)	3.3 ± 0.8	3.2 ± 0.1	ns
FT4 (pmol/L)	10.6 ± 0.3	11.7 ± 0.4	< 0.006

Data are reported as mean ± SD; ns= Not significant

Table 2. Diagnoses of patients with hypogonadism not due to Klinefelter syndrome (control group)

	Number of cases
Kallmann syndrome	33
After pituitary surgery	8
Idiopathic	17
Iatrogenic	4
Total	62



Change of authorship request form (pre-acceptance)

Please read the important information on page 4 before you begin

This form should be used by authors to request any change in authorship including changes in corresponding authors. Please fully complete all sections. Use black ink and block capitals and provide each author's full name with the given name first followed by the family name.

Please note: In author collaborations where there is formal agreement for representing the collaboration, it is sufficient for the representative or legal guarantor (usually the corresponding author) to complete and sign the Authorship Change Form on behalf of all authors.

Manuscript ID no. in case of unpublished manuscript: JENI-D-18-00755R1
DOI in case of published manuscript:
ISBN (for books):

Section 1: Please provide the current title of manuscript if
 (For journals: Please provide the manuscript ID, title and/or DOI if available.)
 (For books: Please provide the title, ISBN and/or DOI if available.)

Title: Thyroid function in Klinefelter syndrome: a multicenter study from KING group

Section 2: Please provide the previous authorship, in the order shown on the manuscript before the changes were introduced. Please indicate the corresponding author by adding (CA) behind the name.

	First name(s)	Family name	ORCID or SCOPUS id, if available
1 st author	GIANCARLO	BAUERCIN	
2 nd author	BLANCO	BONOMI	
3 rd author	VITO A.	GIAGUCCI	
4 th author	FABIO	LANFRANCO	
5 th author	VINCENZO	ROCHINA	
6 th author	ANTONIO	GIAMBERSIO	
7 th author	GIAGUCCI	ACCANNO	

Please use an additional sheet if there are more than 7 authors.

3: Section 3: Please provide a justification for change. Please use this section to explain your reasons for changing the authorship of your manuscript, e.g. what necessitated the change in authorship? Please refer to the (journal) policy pages for more information about authorship. Please explain why omitted authors were not originally included and/or why authors were removed on the submitted manuscript.

We decided to add to the authors of this manuscript Prof. Aldo Calogerò and Dr Rosita A. Condorelli, who already belong to the KING group, for their valuable contribution to the revision of the manuscript

4: Section 4: Proposed new authorship. Please provide your new authorship list in the order you would like it to appear on the manuscript. Please indicate the corresponding author by adding (CA) behind the name. If the corresponding author has changed, please indicate the reason under section 3.

	First name(s)	Family name (this name will appear in full on the final publication and will be searchable in various abstract and index databases)
1 st author	Giancarlo	Balercia
2 nd author	Marco	Bonomi
3 rd author	Vito A.	Giagulli
4 th author	Fabio	Lanfranco
5 th author	Vincenzo	Rochira
6 th author	Antonio	Giambersio
7 th author	Giacomo	Accardo

Please use an additional sheet if there are more than 7 authors.

Change of authorship request form (pre-acceptance)

Section 5: Author contribution, Acknowledgement and Disclosures. Please use this section to provide a new disclosure statement and, if appropriate, acknowledge any contributors who have been removed as authors and ensure you state what contribution any new authors made (if applicable per the journal or book (series) policy). Please ensure these are updated in your manuscript after approval of the change(s) - as our production department will not transfer the information in this form to your manuscript.

New acknowledgements:

New Disclosures (financial and non-financial interests, funding): The authors have nothing to disclose

New Author Contributions statement (if applicable per the journal policy):

State 'Not applicable' if there are no new authors.

SPRINGER NATURE

Springer Nature is one of the world's leading global research, educational and professional publishers created in May 2015 through the combination of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media.

Change of authorship request form (pre-acceptance)

Section 6: Declaration of agreement. All authors, unchanged, new and removed must sign this declaration.


(NB: Please print the form, sign and return a scanned copy. Please note that signatures that have been inserted as an image file are acceptable as long as it is handwritten. Typed names in the signature box are unacceptable.) * Please delete as appropriate. Delete all of the bold if you were on the original authorship list and are remaining as an author.

First name	Family name	Signature	Affiliated institute	Date
1 st author Giancarlo	Balercia	<i>G Balercia</i>	Division of Endocrinology, Department of Clinical and Molecular Sciences, Umberto I Hospital, Polytechnic University of Marche, Ancona, Italy	14.3.2019
2 nd author Marco	Bonomi	<i>M Bonomi</i>	Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy	14.3.2019
3 rd author Vito A	Giagulli	<i>V Giagulli</i>	Outpatient Clinic for Endocrinology and Metabolic Diseases, Conversano Hospital, Conversano, Bari, Italy	14.3.2019
4 th authors Fabio	Lanfranco	<i>F Lanfranco</i>	Division of Endocrinology, Diabetology, and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy	14.3.2019
5 th author Vincenzo	Rochira	<i>V Rochira</i>	Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy	14.3.2019
6 th author Antonio	Giambersio	<i>A Giambersio</i>	Health Center "Maria Teresa di Calcutta" Pienza, Pienza, Italy	14.3.2019
7 th author Giacomo	Accardo	<i>G Accardo</i>	Department of Advanced Medical And Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy	14.3.2019

Please use an additional sheet if there are more than 7 authors.

Important information. Please read.

- Please return this form, fully completed, to Springer Nature. We will consider the information you have provided to decide whether to approve the proposed change in authorship. We may choose to contact your institution for more information or undertake a further investigation, if appropriate, before making a final decision.
- By signing this declaration, all authors guarantee that the order of the authors are in accordance with their scientific contribution, if applicable as different conventions apply per discipline, and that only authors have been added who made a meaningful contribution to the work.
- Please note, we cannot investigate or mediate any authorship disputes. If you are unable to obtain agreement from all authors (including those who you wish to be removed) you must refer the matter to your institution(s) for investigation. Please inform us if you need to do this.
- If you are not able to return a fully completed form within 30 days of the date that it was sent to the author requesting the change, we may have to withdraw your manuscript. We cannot publish manuscripts where authorship has not been agreed by all authors (including those who have been removed).
- Incomplete forms will be rejected.

Bohn
Stafleu
van Loghum

Springer

Change

Change of authorship request form (pre-acceptance)

Please read the important information on page 4 before you begin

This form should be used by authors to request any change in authorship including changes in corresponding authors. Please fully complete all sections. Use black ink and block capitals and provide each author's full name with the given name first followed by the family name.

Please note: In author collaborations where there is formal agreement for representing the collaboration, it is sufficient for the representative or legal guarantor (usually the corresponding author) to complete and sign the Authorship Change Form on behalf of all authors.

Manuscript ID no. in case of unpublished manuscript: JENI-D-18-00755R1

DOI in case of published manuscript:

ISBN (for books):

Section 1: Please provide the current title of manuscript

(For journals: Please provide the manuscript ID, title and/or DOI if available.)

(For books: Please provide the title, ISBN and/or DOI if available.)

Title: Thyroid function in Klinefelter syndrome: a multicenter study from KING group

Section 2: Please provide the previous authorship, in the order shown on the manuscript before the changes were introduced. Please indicate the corresponding author by adding (CA) behind the name.

	First name(s)	Family name	ORCID or SCOPUS id, if available
1 st author	Daniela,	Esposito	
2 nd author	Stefano,	Allasia	
3 rd author	Biagio,	Cangian	
4 th author	Sara	De Vincentiis	
5 th author	Daniela	Pasquali CA	
6 th author			
7 th author			

Please use an additional sheet if there are more than 7 authors.

SPRINGER NATURE

Springer Nature is one of the world's leading global research, educational and professional publishers, created in May 2015 through the combination of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media.



Change of authorship request form (pre-acceptance)

Section 3: Please provide a justification for change. Please use this section to explain your reasons for changing the authorship of your manuscript, e.g. what necessitated the change in authorship. Please refer to the (journal) policy pages for more information about authorship. Please explain why omitted authors were not originally included and/or why authors were removed on the submitted manuscript.

We decided to add to the authors of this manuscript Prof Aldo Calogero and Dr Rosita A. Vignera, who already belong to the KING group, for their valuable contribute to the revision of the manuscript

4: Section 4: Proposed new authorship. Please provide your new authorship list in the order you would like it to appear on the manuscript. Please indicate the corresponding author by adding (CA) behind the name. If the corresponding author has changed, please indicate the reason under section 3.

	First name(s)	Family name (this name will appear in full on the final publication and will be searchable in various abstract and indexing databases)
1 st author	Daniela	Esposito
2 nd author	Stefano	Allasia
3 rd author	Sara	De Vincentiis
4 th author	Biagio	Cangiano
5 th author	Rosita A	Condorelli
6 th author	Aldo	Calogero
7 th author	Daniela	Pasquali CA

Please use an additional sheet if there are more than 7 authors.

Section
have been
your
New
New
New
State

5:

Section 5: Author contribution, Acknowledgement and Disclosures. Please use this section to provide a new disclosure statement and, if appropriate, acknowledge any contributors who have been removed as authors and ensure you state what contribution any new authors made (if applicable per the journal or book (series) policy). Please ensure these are updated in your manuscript, after approval of the change(s) - as our production department will not transfer the information in this form to your manuscript.

New acknowledgements:

New Disclosures (financial and non-financial interests, funding): The authors have nothing to disclose








New Author Contributions statement (if applicable per the journal policy):

State 'Not applicable' if there are no new authors.

Change of authorship request form (pre-acceptance)

Section 6: Declaration of agreement. All authors, unchanged, new and removed **must** sign this declaration.

(NB: Please print the form, sign and return a scanned copy. Please note that signatures that have been inserted as an image file are acceptable as long as it is handwritten. Typed names in the signature box are unacceptable.) * Please delete as appropriate. Delete all of the bold if you were on the original authorship list and are remaining as an author.

	First name	Family name		Signature	Affiliated institute	Date
1st author	Daniela	Esposito	I agree to the proposed new authorship shown in section 4 and the addition/removal of my name to the authorship list.		Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden	14.3.2019
2nd author	Stefano	Allasia	I agree to the proposed new authorship shown in section 4 and the addition/removal of my name to the authorship list.		Division of Endocrinology, Diabetology, and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy	14.3.2019
3rd author	Biagio	Cangiano	I agree to the proposed new authorship shown in section 4 and the addition/removal of my name to the authorship list.		Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy	14.3.2019
4th authors	Sara	De Vincentis	I agree to the proposed new authorship shown in section 4 and the addition/removal of my name to the authorship list.		Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena	14.3.2019
5th author	Rosita A	Condorelli	I agree to the proposed new authorship shown in section 4 and the addition/removal of my name to the authorship list.		Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Catania, Italy	14.3.2019
6th author	Aldo	Calogero	I agree to the proposed new authorship shown in section 4 and the addition/removal of my name to the authorship list.		Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Catania, Italy	14.3.2019
7th author	Daniela	Pasquali	I agree to the proposed new authorship shown in section 4 and the addition/removal of my name to the authorship list.		Department of Advanced Medical And Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy	14.3.2019

Please use an additional sheet if there are more than 7 authors.

Change of authorship request form (pre-acceptance)

Important information. Please read.

- Please return this form, fully completed, to Springer Nature. We will consider the information you have provided to decide whether to approve the proposed change in authorship. We may choose to contact your institution for more information or undertake a further investigation, if appropriate, before making a final decision.
- By signing this declaration, all authors guarantee that the order of the authors are in accordance with their scientific contribution, if applicable as different conventions apply per discipline, and that only authors have been added who made a meaningful contribution to the work.
- Please note, we cannot investigate or mediate any authorship disputes. If you are unable to obtain agreement from all authors (including those who you wish to be removed) you must refer the matter to your institution(s) for investigation. Please inform us if you need to do this.
- If you are not able to return a fully completed form within 30 days of the date that it was sent to the author requesting the change, we may have to withdraw your manuscript. We cannot publish manuscripts where authorship has not been agreed by all authors (including those who have been removed).
- Incomplete forms will be rejected.